Aethlon Medical, Inc. (AEMD) stock soared 20.26% in the pre-market trading session at the price of $4.57 despite no recent updates. The last reported news on the company’s website was its first-quarter 2021 financial results. AEMD is a leading global health company focused on addressing the unmet needs of patients. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device that fights against cancer and fatal infections.  

AEMD First Quarter 2021 Financial Results and Corporate Updates 

 On 9th August 2021, AEMD announced financial results for its first quarter ended 30th June 2021, and provided recent business developments. AEMD reported a net loss of $2.09 million in the second quarter ended 30th June 2021, compared to the net loss of $1.4 million in the same quarter of the previous year. Basic and diluted net loss available to common stockholders was $(0.16) per share in the second quarter of 2021, compared to the net loss of $(0.15) per share in the same period of 2020. 

Aethlon Medical had a $25.2 million cash balance on 30th June 2021. For the three months ended on 30th June 2021, the company earned approximately $17.5 million in net proceeds from the common stock. AEMD reported government contract revenue of $115,000 on its Phase 2 Melanoma Cancer Contract in the first quarter ended 30th June 2021. For the three months ended on 30th June 2021, the consolidated operating expenses were approximately $2.2 million. Consolidated operating expenses were $1.4 million for the three months ended on 30th June 2020. This $800,000 or 58% gain in the 2021 quarter resulted from higher payroll and related expenses of $580,000 and administrative expenses of $221,000.  

Fiscal Year 2021 Financial Results and Corporate Updates 

 On 24th June 2021, AEMD announced financial results for its fiscal year ended 31st March 2021 and provided corporate updates. For the fiscal year ended 31st March 2021, consolidated operating expenses were $8.6 million, compared to approximately $6.6 million for the fiscal year ended 31st March 2020. AEMD reported a net loss of $7.9 million for the fiscal year ended 31st March 2021. The reported net loss was $6.4 million for the fiscal year ended 31st March 2020. The company reported a cash balance of $9.9 million on 31st March 2021. The government contract revenue was $659,000 in fiscal 2021 compared to $650,000 in the fiscal year ended 31st March 2020.